Zuellig Pharma Korea said on Friday that it appointed Dr. Marc Franck, former CEO of Zuellig Pharma Vietnam, as the new head of the Korean branch.Over the past 22 years, he has served in senior management positions in various countries where DKSH and Zuellig Pharma corporations are located, speciali
A research team from Korea University's Anam Hospital and Soongsil University discovered that high blood pressure is closely associated with infectious endocarditis through a recent domestic big data analysis.Infectious endocarditis is a fatal infectious disease with high mortality rates of about 20
Immunovant Sciences, the U.S. partner of Hanall Biopharma, is speeding up a phase 3 trial of HL161 (batoclimab), an autoimmune disease treatment candidate that it licensed from Hanall.Hanall Biopharma said Immunovant started the phase 3 study of HL161 (Immunovant’s pipeline name: IMVT-1401) to treat
For Korean pharmaceutical and biotech companies, biosimilars used to be the new source of income. Especially after Celltrion and Samsung Bioepis successfully released biosimilars in the global market, many local pharmaceutical and biopharma firms have jumped into developing biosimilars.Chong Kun Dan
GI Innovation said it obtained a substance patent of GI-101, its key immunotherapy candidate, in the U.S.On Monday, the company said it registered the GI-101 patent with a wide range of rights without amino sequence restrictions in the U.S. which accounts for 60 percent of the global biopharmaceutic
The organizers of the first International Virus and Bacterial Industry Expo in Korea have recently signed a business agreement with the Association of American States Offices in Korea (ASOK) for the successful hosting of the event.The Int’l Virus & Bacteria Industry Expo is the first such event to b
Celltrion Healthcare has started a study to evaluate the effect of replacing Humira (ingredient: adalimumab), an autoimmune disease treatment developed by AbbVie, with Yuflyma in France.According to Clinicaltrials.gov, a clinical information site run by the U.S. National Institutes of Health, Celltr
Siemens Healthineers said Friday it would participate in the 24th International Congress of Clinical Chemistry and Laboratory Medicine at IFCC WorldLab Seoul 2022 from June 26-30 as a “gold sponsor.”It is the first time Korea will host the conference of about 50 global businesses, which will be held
The biosimilar market is drawing much attention, especially after Celltrion and Samsung Bioepis became one of the leaders in the global biosimilar market.Other Korean pharmaceutical and biotech companies – such as Chong Kun Dang, Dong-A ST, LG Chem, Alteogen, and Prestige Biopharma – are pushing to
The National Institute of Food and Drug Safety Evaluation (NIFDS) under the Ministry of Food and Drug Safety said Thursday that it has significantly contributed to international cooperation for biopharmaceutical standardization and would continue to do so.The institute resolved so while publishing a
A Korea-Japan joint research team has developed the first skin-integrated antibacterial nano-mesh patch, which prevents infection while maintaining the skin's unique condition and sensation.Kwon Oh-seok of the Korea Research Institute of Bioscience and Biotechnology (KRIBB), Professor Someya Takao o
Samsung Bioepis chose Samil Pharmaceutical, a strong player in eye disease treatments, to enter the Korean Lucentis biosimilar market for the first time. Lucentis is a treatment for various ophthalmic diseases.The partnership will make Samil a key rival against Chong Kun Dang in Lucentis biosimilar
DIO said Monday it has signed a product training and supply contract with a global dental service organization (DSO), following a previous supply agreement with another large distributor with 100,000 dental clinics in the U.S.DIO said it would provide sequential training on its digital implant "DIOn
SK Bioscience, which once made a strong stock market debut in March last year, is now struggling with sliding price of its shares on Kospi.Analysts said that to boost the stock price struggling to surpass 100,000 won ($77.4), the company has to present investors with detailed achievements from the v
The Seoul National University Bundang Hospital (SNUBH) set up a "K-Bio Health Regional Center" in a ceremony Tuesday in line with a government project supporting the commercialization of biohealth technology.SNUBH President and CEO Paik Nam-jong, Seongnam Mayor Eun Soo-mi, Ryu Hae-pil, director of S
Curocell said its investigational CAR-T therapy anbal-cell (ingredient: anbalcabtagene autoleucel) showed an 82 percent complete response rate in patients with relapsed/refractory large B-cell lymphoma (LBCL).Professor Kim Won-seog of hemato-oncology at Samsung Medical Center, who was the principal
Immunovant, the U.S. partner of Hanall Biopharma, said it would develop additional indications for HL161 (batoclimab), an autoimmune disease treatment candidate it licensed from Hanall. Accordingly, Hanall Biopharma is expected to receive an additional milestone payment from Immunovant.In a conferen
The Ministry of Health and Welfare and the Korea Health Industry Development Institute opened a C&D (connect and develop) incubation center at the Cambridge Innovation Center (CIC) in Boston, Mass., on Wednesday (EST).The ministry and the institute set up the C&D incubation center, named Korea Bio-I
TiumBio, a Korean biotech company focusing on cancer and rare diseases, said it would participate in the 2022 BIO International Convention (BIO USA) to discuss partnerships with multinational drugmakers and biotech firms.BIO USA is the world’s largest biotech and pharmaceutical partnering event. Thi
Johnson & Johnson Innovation and Janssen Korea launched the sixth “Seoul Innovation QuickFire Challenge: Scientific Advancements of Tomorrow” in collaboration with the Seoul Metropolitan Government (SMG) and the Korea Health Industry Development Institute (KHIDI).J&J’s QuickFire Challenge aims to ad